Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON8 Trials Programme
ISRCTN10356387Phase 3Completed
- Sponsor
- MRC Clinical Trials Unit at UCL (UK)
- Start
- Apr 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel and bevacizumab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more (6 arms), sponsored by MRC Clinical Trials Unit at UCL (UK). Primary endpoints: Progression-free survival and Overall survival. Started Apr 2011; status: completed.
02
Drugs
carboplatinpaclitaxelbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)ovarian carcinosarcoma (OCS)
Beyond the preview
Go deeper on ISRCTN10356387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10356387.